Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Hashimoto’s Thyroiditis in Down’s Syndrome: Clinical Presentation and Evolution

Popova G.a · Paterson W.F.b · Brown A.c · Donaldson M.D.C.b

Author affiliations

aUniversity Children’s Hospital, Sofia, Bulgaria; bDepartment of Child Health, and cScottish National Neonatal Screening Laboratory, Royal Hospital for Sick Children, Glasgow, UK

Related Articles for ""

Horm Res 2008;70:278–284

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 30, 2007
Accepted: December 06, 2007
Published online: September 30, 2008
Issue release date: November 2008

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 0

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP

Abstract

Aim: It was the aim of this study to describe the presentation and clinical course of Hashimoto’s thyroiditis (HT) in children with Down’s syndrome (DS) in 2 Scottish health regions. Patients and Methods: We retrospectively analysed clinical, biochemical and thyroid antibody status in 38 patients with DS with HT diagnosed from 1989 to 2004. Results: The sex distribution was similar (20 males, 18 females), with a median age of 12.3 years (range 2.1–17.7). Of the 38 patients reviewed, 29 were identified by screening. A goitre was present in 6/38 patients. Thyroid antibodies were positive in 36/38 patients, negative in 1/38, and data were unavailable for 1/38. At presentation, 37/38 patients were hypothyroid: 21/37 with compensated hypothyroidism (6 treated initially) and 16/37 with decompensated hypothyroidism (all treated). Of the 15/21 compensated patients who were untreated initially, only 3 remitted while 12 showed disease progression prompting treatment. In the decompensated group, 1/16 patient pursued a fluctuating course between hypo- and hyperthyroidism. The final patient, who was hyperthyroid at presentation, also showed marked fluctuation in thyroid function over a 5-year period. Conclusion: The natural history of HT in DS is unusual, with no female predominance and infrequent goitre in our cohort. While almost all patients required treatment eventually, clinicians should be aware that the disease may pursue a fluctuating course between hypo- and hyperthyroidism.

© 2008 S. Karger AG, Basel


References

  1. Fort P, Lifshitz F, Bellisario R, Davis J, Lanes R, Pugliese M, Richman R, Post EM, David R: Abnormalities of thyroid function in infants with Down syndrome. J Pediatr 1984;104:545–549.
  2. Cutler AT, Benezra-Obeiter R, Brink SJ: Thyroid function in young children with Down syndrome. Am J Dis Child 1986;140:479–483.
  3. Oakley GA, Muir T, Ray M, Girdwood RWA, Kennedy R, Donaldson MDC: Increased incidence of congenital malformations in children with transient thyroid-stimulating hormone elevation on newborn screening. J Pediatr 1998;132:726–730.
  4. Shalitin S, Phillip M: Autoimmune thyroiditis in infants with Down’s syndrome. J Pediatr Endocrinol 2002;15:649–652.
    External Resources
  5. Idris I, O’Malley BP: Thyrotoxicosis in Down’s and Turner’s syndromes: the likelihood of Hashimoto’s thyroiditis as the underlying aetiology. Int J Clin Pract 2000;54:272–273.
  6. Rudberg C, Johansson H, Akerstrom G, Tuvema T, Karlsson FA: Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996;134:710–715.
  7. Prasher VP: Reliability of diagnosing clinical hypothyroidism in adults with Down syndrome. Aust NZ J Dev Disabil 1995;20:223–233.
  8. DSMIG: Basic medical surveillance essentials for people with Down’s syndrome. Recommendations of the Down’s Syndrome Medical Interest Group, Thyroid Disorder. 2001. www.dsmig.org.uk.
  9. Noble SE, Leyland K, Findlay CA, Clark CE, Redfern J, Mackenzie JM, Girdwood RWA, Donaldson MDC: School based screening for hypothyroidism in Down’s syndrome by dried blood spot TSH measurement. Arch Dis Child 2000;82:27–31.
  10. Sharav T, Collins RM, Baab PJ: Growth studies in infants and children with Down’s syndrome and elevated levels of thyrotropin. Am J Dis Child 1988;142:1302–1306.
  11. Selikowitz M: A five-year longitudinal study of thyroid function in children with Down syndrome. Dev Med Child Neurol 1993;35:396–401.
  12. Marasco JA Jr, Feczko WA: Basal ganglia calcification in Down’s syndrome. Comput Tomogr 1979;3:111–113.
  13. Lobo Ede H, Khan M, Tew J: Community study of hypothyroidism in Down’s syndrome. BMJ 1980;24:1253.
    External Resources
  14. Tuysuz B, Beker DB: Thyroid dysfunction in children with Down’s syndrome. Acta Paediatr 2001;90:1389–1393.
  15. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Anneren G: Thyroid dysfunction in Down’s syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998;79:242–245.
  16. Fargas A, Martinez J, Dominguez P, Albert DC, Yeste D, Toran N: Thirteen month old girl with Down syndrome, pericardial effusion and hypothyroidism. Pediatria Catalana 1996;56:39–42.
  17. Zori RT, Schatz DA, Ostrer H, Williams CA, Spillar R, Riley WJ: Relationship of autoimmunity to thyroid dysfunction in children and adults with Down syndrome. Am J Med Genet Suppl 1990;7:238–241.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 30, 2007
Accepted: December 06, 2007
Published online: September 30, 2008
Issue release date: November 2008

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 0

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.